Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)
Triggering receptor expressed on myeloid cells (TREM)-1 is a recently described molecule that plays an important role in myeloid cell-activated inflammatory responses. The aim of this study was to investigate the evolutional change of soluble TREM-1 (sTREM-1) in bronchoalveolar lavage (BAL) fluid of clinically diagnosed ventilator-associated pneumonia (VAP) and its correlation with response to treatment and outcome.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia|
- mortality [ Time Frame: 18 months ] [ Designated as safety issue: No ]
|Study Start Date:||August 2006|
|Study Completion Date:||September 2008|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
Procedure: Bronchoscopy BAL
The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
A prospective, interventional study conducted between August 2006 and August 2007 in MICU in Mackay Memorial Hospital, 35 patients with clinically diagnosed VAP were investigated. sTREM-1 was measured in BAL samples using ELISA at the onset, 4th - 5th and 7th - 9th day of clinical diagnosis of VAP.Of these 35 patients, 27 had positive BAL culture. The sTREM-1 levels in BAL fluid were measured and compared between patients with positive BAL culture and negative BAL culture. Serial changes in sTREM-1 levels were evaluated in relation to patient outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00976157
|Mackay Memorial Hospital|
|Taipei, Taiwan, 106|
|Principal Investigator:||Chien Liang Wu, MD||Mackay Memorial Hospital, Taipei, Taiwan|